BLS Pharmaceuticals has entered a non-binding heads of agreement with Trexapharm to explore the Australian commercialisation of TREXAVIVE, a proprietary, patented neurotherapy being developed for treatment-resistant depression.
Under the proposed collaboration, BLS would become Trexapharm’s preferred Australian commercial partner, using its manufacturing capabilities, commercial infrastructure and existing relationships with psychiatrists, clinics and healthcare providers to support patient access and future supply.
Managing Director Sam Watson said, "Treatment-resistant depression is not just a diagnosis, it is a daily battle for millions of people that harms motivation, relationships and hope. Too many patients simply run out of options when standard therapies fail. This proposed collaboration gives us the opportunity to support the introduction of differentiated, non-sedating treatment options to Australian psychiatrists and their patients, alongside our existing work in medicinal cannabis and psychedelic medicines."
Trexapharm will remain responsible for the clinical development and retain ownership of the intellectual property for TREXAVIVE, which is protected by patents in Australia and the United States and by additional international patent applications.
Trexapharm’s Executive Chairman Lee Rodne explained why BLS was chosen and how the partnership could grow. "We have been looking for the right commercial partner to help bring TREXAVIVE to Australian patients, and BLS stood out because of its established pharmaceutical manufacturing capabilities, commercial infrastructure and growing leadership in regulated mental health therapies. We believe this collaboration provides a strong platform to expand patient access while continuing the clinical development of TREXAVIVE, and we look forward to working together as the relationship evolves."
TREXAVIVE is designed as a non-sedating outpatient therapy that combines low doses of flumazenil and naltrexone for delivery within existing psychiatric settings.
The heads of agreement sets a framework for negotiating definitive commercial arrangements and includes exploration of Australian manufacturing options such as subcutaneous infusion and nasal spray delivery. The parties also intend to evaluate patient access pathways through the Therapeutic Goods Administration Special Access Scheme category B and Authorised Prescriber routes, and to consider opportunities in veteran and defence mental health, international markets and potential strategic investment and supply arrangements.
